SK Biopharmaceuticals Co Ltd
KRX:326030
SK Biopharmaceuticals Co Ltd
KRX:326030
Price:
103 000
KRW
0.88%
Market Closed
Market Cap:
8.1T
KRW
Income Statement
Earnings Waterfall
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
|
Revenue
|
547.6B
KRW
|
|
Cost of Revenue
|
-43.1B
KRW
|
|
Gross Profit
|
504.5B
KRW
|
|
Operating Expenses
|
-408.2B
KRW
|
|
Operating Income
|
96.3B
KRW
|
|
Other Expenses
|
144.4B
KRW
|
|
Net Income
|
240.7B
KRW
|
Income Statement
SK Biopharmaceuticals Co Ltd
SK Biopharmaceuticals Co Ltd
Currency: KRW
Millions
TTM
| Dec-2019 | Mar-2020 | Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||||
| Revenue |
123 852
N/A
|
10 717
-91%
|
6 274
-41%
|
10 115
+61%
|
25 999
+157%
|
162 060
+523%
|
183 964
+14%
|
203 992
+11%
|
418 645
+105%
|
319 801
-24%
|
349 264
+9%
|
414 148
+19%
|
246 179
-41%
|
265 819
+8%
|
289 399
+9%
|
290 903
+1%
|
354 892
+22%
|
408 082
+15%
|
465 064
+14%
|
511 328
+10%
|
547 596
+7%
|
|
| Gross Profit | ||||||||||||||||||||||
| Cost of Revenue |
(514)
|
(916)
|
(1 653)
|
(1 985)
|
(1 974)
|
(3 419)
|
(4 693)
|
(6 581)
|
(22 336)
|
(26 501)
|
(32 372)
|
(43 390)
|
(37 768)
|
(35 695)
|
(37 114)
|
(30 671)
|
(34 082)
|
(42 090)
|
(41 461)
|
(51 198)
|
(43 101)
|
|
| Gross Profit |
123 338
N/A
|
9 801
-92%
|
4 621
-53%
|
8 130
+76%
|
24 025
+196%
|
158 641
+560%
|
179 271
+13%
|
197 410
+10%
|
396 309
+101%
|
293 300
-26%
|
316 893
+8%
|
370 758
+17%
|
208 411
-44%
|
230 124
+10%
|
252 285
+10%
|
260 232
+3%
|
320 809
+23%
|
365 992
+14%
|
423 603
+16%
|
460 130
+9%
|
504 495
+10%
|
|
| Operating Income | ||||||||||||||||||||||
| Operating Expenses |
(202 597)
|
(229 844)
|
(242 143)
|
(258 168)
|
(263 524)
|
(257 090)
|
(284 966)
|
(290 007)
|
(301 350)
|
(311 411)
|
(309 995)
|
(323 169)
|
(339 489)
|
(346 720)
|
(331 569)
|
(357 157)
|
(358 331)
|
(370 562)
|
(383 192)
|
(392 831)
|
(408 156)
|
|
| Selling, General & Administrative |
(22 615)
|
(56 682)
|
(83 883)
|
(96 759)
|
(145 577)
|
(139 715)
|
(157 325)
|
(161 995)
|
(176 567)
|
(187 007)
|
(184 412)
|
(195 744)
|
(205 113)
|
(209 192)
|
(210 195)
|
(211 829)
|
(208 771)
|
(213 411)
|
(213 910)
|
(220 251)
|
(234 124)
|
|
| Research & Development |
(176 213)
|
(168 619)
|
(154 556)
|
(155 759)
|
(108 441)
|
(75 948)
|
(85 702)
|
(86 397)
|
(113 142)
|
(113 560)
|
(114 122)
|
(115 247)
|
(121 392)
|
(124 316)
|
(124 018)
|
(131 158)
|
(134 243)
|
(140 843)
|
(152 149)
|
(151 953)
|
(158 539)
|
|
| Depreciation & Amortization |
(3 769)
|
(4 544)
|
(5 653)
|
(7 627)
|
(9 506)
|
(10 245)
|
(10 755)
|
(10 432)
|
(11 642)
|
(10 844)
|
(11 460)
|
(12 178)
|
(12 984)
|
(13 212)
|
(13 532)
|
(14 170)
|
(15 317)
|
(16 309)
|
(17 132)
|
(17 459)
|
(15 493)
|
|
| Other Operating Expenses |
0
|
0
|
1 949
|
1 977
|
0
|
(31 183)
|
(31 183)
|
(31 183)
|
0
|
0
|
0
|
0
|
0
|
0
|
16 176
|
0
|
0
|
0
|
0
|
(3 168)
|
0
|
|
| Operating Income |
(79 259)
N/A
|
(220 043)
-178%
|
(237 523)
-8%
|
(250 039)
-5%
|
(239 499)
+4%
|
(98 450)
+59%
|
(105 695)
-7%
|
(92 597)
+12%
|
94 958
N/A
|
(18 111)
N/A
|
6 898
N/A
|
47 588
+590%
|
(131 078)
N/A
|
(116 596)
+11%
|
(79 285)
+32%
|
(96 925)
-22%
|
(37 522)
+61%
|
(4 570)
+88%
|
40 411
N/A
|
67 299
+67%
|
96 340
+43%
|
|
| Pre-Tax Income | ||||||||||||||||||||||
| Interest Income Expense |
(2 645)
|
(2 290)
|
(2 519)
|
(2 101)
|
140
|
4 214
|
5 089
|
10 021
|
(72 438)
|
(73 709)
|
(76 774)
|
(89 725)
|
(15 452)
|
(9 554)
|
(11 375)
|
(9 381)
|
(11 486)
|
(21 900)
|
(20 018)
|
(24 425)
|
(24 615)
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
50 350
|
50 350
|
50 350
|
49 269
|
(824)
|
(824)
|
(824)
|
4 317
|
16 176
|
0
|
12 536
|
5 308
|
(6 808)
|
(6 808)
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
(2 007)
|
(2 007)
|
0
|
(2 007)
|
(0)
|
(3)
|
(3)
|
(3)
|
(3)
|
0
|
(9)
|
(10)
|
(11)
|
0
|
(12)
|
(12)
|
(19)
|
0
|
162
|
162
|
171
|
|
| Total Other Income |
(541)
|
(248)
|
(1 816)
|
(519)
|
(550)
|
(570)
|
(1 032)
|
(520)
|
(509)
|
(450)
|
(413)
|
(269)
|
(245)
|
21
|
(44)
|
(139)
|
(139)
|
(327)
|
1 494
|
1 531
|
700
|
|
| Pre-Tax Income |
(84 451)
N/A
|
(224 589)
-166%
|
(241 858)
-8%
|
(254 666)
-5%
|
(239 909)
+6%
|
(44 459)
+81%
|
(51 290)
-15%
|
(32 749)
+36%
|
71 277
N/A
|
(93 095)
N/A
|
(71 123)
+24%
|
(43 239)
+39%
|
(142 469)
-229%
|
(109 953)
+23%
|
(90 715)
+17%
|
(93 921)
-4%
|
(43 858)
+53%
|
(33 605)
+23%
|
15 243
N/A
|
44 568
+192%
|
72 596
+63%
|
|
| Net Income | ||||||||||||||||||||||
| Tax Provision |
12 932
|
12 045
|
12 321
|
12 299
|
(7 504)
|
(7 369)
|
(7 905)
|
(7 647)
|
(6 431)
|
(6 255)
|
(6 634)
|
(5 206)
|
3 038
|
3 359
|
6 182
|
5 936
|
8 478
|
10 293
|
9 345
|
4 742
|
154 378
|
|
| Income from Continuing Operations |
(71 519)
|
(212 544)
|
(229 537)
|
(242 367)
|
(247 414)
|
(51 828)
|
(59 196)
|
(40 396)
|
64 846
|
(99 351)
|
(77 756)
|
(48 445)
|
(139 431)
|
(106 594)
|
(84 533)
|
(87 985)
|
(35 379)
|
(23 313)
|
24 588
|
49 310
|
226 973
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
4 483
|
2 497
|
5 631
|
9 209
|
8 072
|
13 765
|
|
| Net Income (Common) |
(71 519)
N/A
|
(212 544)
-197%
|
(229 537)
-8%
|
(242 367)
-6%
|
(247 414)
-2%
|
(51 828)
+79%
|
(59 196)
-14%
|
(40 396)
+32%
|
64 846
N/A
|
(99 351)
N/A
|
(77 756)
+22%
|
(48 445)
+38%
|
(139 431)
-188%
|
(106 594)
+24%
|
(84 533)
+21%
|
(83 502)
+1%
|
(32 883)
+61%
|
(17 682)
+46%
|
33 796
N/A
|
57 383
+70%
|
240 738
+320%
|
|
| EPS (Diluted) |
-1 100.3
N/A
|
-3 269.9
-197%
|
-3 531.33
-8%
|
-3 107.26
+12%
|
-3 447.52
-11%
|
-661.8
+81%
|
-755.88
-14%
|
-515.82
+32%
|
828.03
N/A
|
-1 268.63
N/A
|
-992.89
+22%
|
-618.6
+38%
|
-1 780.43
-188%
|
-1 361.12
+24%
|
-1 079.42
+21%
|
-1 066.26
+1%
|
-419.89
+61%
|
-225.79
+46%
|
431.55
N/A
|
732.73
+70%
|
3 074.04
+320%
|
|
Switch to:
Switch to:
See Also
Discover More
You don't have any saved screeners yet
